Free Newsletter
Nanotech grows more common in drug dev research
Nanotechnology, including nanoscale drug delivery devices, is becoming steadily more common in the field of drug development and research. One example of this trend comes from Accelrys, which specializes in developing software for use in drug development work. Accelrys has enlisted some high-powered scientific help to broaden their level of expertise. MIT scientist Dr. Robert Langer has been brought in to provide additional insight into ways that software can be used to model new approaches in nanobiology. Article
More stories about nanotechnology
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: